CDMO Kindeva Drug Delivery has announced that it will invest in a second MDI manufacturing line capable of filling lower global warming potential (GWP) propellants such as HFA 152a and HFO 1234ze in response to increasing demand. The company announced plans to install its first lower-GWP propellant filling line in November 2021. The new line is expected to be installed at the company’s Loughborough, UK facility by the end of 2022.
In May 2021, Kindeva announced that it had partnered with Loughborough University for development of lower-GWP MDI propellants. In the new announcement, Kindeva reaffirmed its plans to get two lower-GWP MDI products to market by 2025 and said that it “is working closely with its partners to drive the commercialization of a portfolio of existing and new pMDI products containing the new low GWP propellants. . .”.
Kindeva CEO Aaron Mann said, “We’re delighted to help the NHS go green. Kindeva has several product development, clinical supply, and manufacturing supply projects underway with a diverse portfolio of large global pharmaceutical companies. These partnerships give us confidence to invest in the future and ensure we have the capacity required to supply low GWP pressurized metered-dose inhalers to meet our clients’ needs. Kindeva intends to install this new manufacturing line by the end of 2022 in response to strong customer demand to reserve this capacity now for development and manufacturing.”
Mann added, “We are excited and honored to be able to continue to increase our manufacturing capacity to help support growing demand for sustainable propellant options from our customers. We are leading this transition to next-generation green propellants, just as we led the industry’s move from CFC to HFA propellants in the 1990s by launching the first CFC-free pMDI globally.”
Read the Kindeva Drug Delivery press release.
